Prenatal exposure to an NMDA receptor antagonist, MK-801 reduces density of parvalbumin-immunoreactive GABAergic neurons in the medial prefrontal cortex and enhances phencyclidine-induced hyperlocomotion but not behavioral sensitization to methamphetamine in postpubertal rats
- 6 March 2007
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 192 (3) , 303-316
Abstract
Rationale Neurodevelopmental deficits of parvalbumin-immunoreactive γ-aminobutyric acid (GABA)ergic interneurons in prefrontal cortex have been reported in schizophrenia. Glutamate influences the proliferation of this type of interneuron by an N-methyl-d-aspartate (NMDA)-receptor-mediated mechanism. The present study hypothesized that prenatal blockade of NMDA receptors would disrupt GABAergic neurodevelopment, resulting in differences in effects on behavioral responses to a noncompetitive NMDA antagonist, phencyclidine (PCP), and a dopamine releaser, methamphetamine (METH). Methods GABAergic neurons were immunohistochemically stained with parvalbumin antibody. Psychostimulant-induced hyperlocomotion was measured using an infrared sensor. Results Prenatal exposure (E15–E18) to the NMDA receptor antagonist MK-801 reduced the density of parvalbumin-immunoreactive neurons in rat medial prefrontal cortex on postnatal day 63 (P63) and enhanced PCP-induced hyperlocomotion but not the acute effects of METH on P63 or the development of behavioral sensitization. Prenatal exposure to MK-801 reduced the number of parvalbumin-immunoreactive neurons even on postnatal day 35 (P35) and did not enhance PCP-induced hyperlocomotion, the acute effects of METH on P35, or the development of behavioral sensitization to METH. Conclusions These findings suggest that prenatal blockade of NMDA receptors disrupts GABAergic neurodevelopment in medial prefrontal cortex, and that this disruption of GABAergic development may be related to the enhancement of the locomotion-inducing effect of PCP in postpubertal but not juvenile offspring. GABAergic deficit is unrelated to the effects of METH. This GABAergic neurodevelopmental disruption and the enhanced PCP-induced hyperlocomotion in adult offspring prenatally exposed to MK-801 may prove useful as a new model of the neurodevelopmental process of pathogenesis of treatment-resistant schizophrenia via an NMDA-receptor-mediated hypoglutamatergic mechanism.Keywords
This publication has 60 references indexed in Scilit:
- Cell and molecular mechanisms involved in the migration of cortical interneuronsEuropean Journal of Neuroscience, 2006
- Cortical inhibitory neurons and schizophreniaNature Reviews Neuroscience, 2005
- Effect of Divalproex Combined with Olanzapine or Risperidone in Patients with an Acute Exacerbation of SchizophreniaNeuropsychopharmacology, 2003
- Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic caseseries outcome studyJournal of Psychopharmacology, 2001
- Ethanol-Induced Apoptotic Neurodegeneration and Fetal Alcohol SyndromeScience, 2000
- Investigation of frontal lobe subregions in first-episode schizophrenia1This study was presented in part at the 1996 Meeting of the Society for Research in Psychopathology in Atlanta, GA, and the 1997 Meeting of the International Congress on Schizophrenia Research in Colorado Springs, CO.1Psychiatry Research: Neuroimaging, 1999
- NMDA receptor antagonists influence early development of GABAergic interneurons in the mammalian striatumDevelopmental Brain Research, 1998
- Refined Crystal Structure of Rat Parvalbumin, a Mammalian α-lineage Parvalbumin, at 2·0 Å ResolutionJournal of Molecular Biology, 1994
- Antagonism of phencyclidine-induced hyperactivity in mice by elevated brain GABA concentrationsPharmacology Biochemistry and Behavior, 1992
- Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animal models of amphetamine psychosisBrain Research Reviews, 1986